Maral Adel Fahmideh1, Judith Schwartzbaum1, Paolo Frumento1, Maria Feychting1. 1. Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden (M.A.F., M.F.); Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.S.); Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden (P.F.).
Abstract
BACKGROUND: Association studies of germline DNA repair single nucleotide polymorphisms (SNPs) and glioma risk have yielded inconclusive results. We therefore performed a systematic review and meta-analysis of studies investigating this association. METHODS: We identified 27 eligible studies investigating 105 SNPs in 42 DNA repair genes. Of these, 10 SNPs in 7 genes were analyzed in at least 4 studies and were therefore included in our meta-analysis. The meta-analysis was performed for homozygote comparison, heterozygote comparison, and dominant and recessive models by applying a fixed- or random-effects model. The funnel and forest plots were created using RevMan software. RESULTS: We found that SNPs rs3212986 (odds ratio [OR] = 1.35 (1.08-1.68), P = .008), rs13181 (OR = 1.18 (1.06-1.31), P = .002), and rs25487 (OR = 1.12 (1.03-1.22), P = .007) in DNA repair genes ERCC1, ERCC2 (XPD), and XRCC1 may increase the risk of glioma, while polymorphisms rs1136410 (OR = 0.78 (0.68-0.89), P = .0004) and rs12917 (OR = 0.84 (0.73-0.96), P = .01) in PARP1(ADPRT) and MGMT are associated with decreased susceptibility to glioma. No evidence of significant associations between ERCC2 rs1799793, OGG1 rs1052133, XRCC1 rs25489, XRCC1 rs1799782, or XRCC3 rs861539 and risk of glioma was observed. CONCLUSION: This study provides evidence that DNA repair genes ERCC1, ERCC2, and XRCC1 might be low-penetrance glioma-risk genes, while MGMT and PARP1 polymorphisms may confer protection against glioma.
BACKGROUND: Association studies of germline DNA repair single nucleotide polymorphisms (SNPs) and glioma risk have yielded inconclusive results. We therefore performed a systematic review and meta-analysis of studies investigating this association. METHODS: We identified 27 eligible studies investigating 105 SNPs in 42 DNA repair genes. Of these, 10 SNPs in 7 genes were analyzed in at least 4 studies and were therefore included in our meta-analysis. The meta-analysis was performed for homozygote comparison, heterozygote comparison, and dominant and recessive models by applying a fixed- or random-effects model. The funnel and forest plots were created using RevMan software. RESULTS: We found that SNPs rs3212986 (odds ratio [OR] = 1.35 (1.08-1.68), P = .008), rs13181 (OR = 1.18 (1.06-1.31), P = .002), and rs25487 (OR = 1.12 (1.03-1.22), P = .007) in DNA repair genes ERCC1, ERCC2 (XPD), and XRCC1 may increase the risk of glioma, while polymorphisms rs1136410 (OR = 0.78 (0.68-0.89), P = .0004) and rs12917 (OR = 0.84 (0.73-0.96), P = .01) in PARP1(ADPRT) and MGMT are associated with decreased susceptibility to glioma. No evidence of significant associations between ERCC2rs1799793, OGG1rs1052133, XRCC1rs25489, XRCC1rs1799782, or XRCC3rs861539 and risk of glioma was observed. CONCLUSION: This study provides evidence that DNA repair genes ERCC1, ERCC2, and XRCC1 might be low-penetrance glioma-risk genes, while MGMT and PARP1 polymorphisms may confer protection against glioma.
Authors: Marc Sanson; Fay J Hosking; Sanjay Shete; Diana Zelenika; Sara E Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean-Yves Delattre; Khe Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao-Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B Robertson; Kenneth Muir; Sarah Hepworth; Anthony Swerdlow; Minouk J Schoemaker; H-Erich Wichmann; Martina Müller; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Asta Försti; Kari Hemminki; Mark Lathrop; Melissa Bondy; Richard S Houlston; Matthias Simon Journal: Hum Mol Genet Date: 2011-04-29 Impact factor: 6.150
Authors: L A Henríquez-Hernández; A Valenciano; P Foro-Arnalot; M J Álvarez-Cubero; J M Cozar; J F Suárez-Novo; M Castells-Esteve; P Fernández-Gonzalo; B De-Paula-Carranza; M Ferrer; F Guedea; G Sancho-Pardo; J Craven-Bartle; M J Ortiz-Gordillo; P Cabrera-Roldán; J I Rodríguez-Melcón; E Herrera-Ramos; C Rodríguez-Gallego; P C Lara Journal: Prostate Cancer Prostatic Dis Date: 2016-01-12 Impact factor: 5.554
Authors: Daniel N Cagney; Joohee Sul; Raymond Y Huang; Keith L Ligon; Patrick Y Wen; Brian M Alexander Journal: Neuro Oncol Date: 2018-08-02 Impact factor: 12.300